Market Overview

Bank of America Comments on FDA Approval of Bruker Corporation's MALDI Biotyper CA System

Share:

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating and $25.00 price target on Bruker Corporation (NASDAQ: BRKR).

In the report, Bank of America noted, “On 11/26, BRKR announced that it received 510-k approval for its MALDI Biotyper CA System, a mass spectrometry based platform for the rapid identification and classification of microorganisms (bacteria, yeasts, and fungi), in-line with mgmt's expectation for a 2H13 approval. Of note, the FDA's approval is specifically for the identification of Gram negative bacterial colonies cultured from human specimens. However, BRKR is working on expanding clearance for Gram positive bacteria and fungi identification and plans to file one of these libraries with the FDA in 1H14.”

Bruker Corporation closed on Wednesday at $19.33.

Latest Ratings for BRKR

DateFirmActionFromTo
Jul 2019UpgradesSellNeutral
May 2019UpgradesMarket PerformOutperform
Apr 2019UpgradesBuy

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Bank of America Derik de BruinAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BRKR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBADowngrades
DLTRUpgrades
ARCCDowngrades
GTYHInitiates Coverage On7.0
NKEMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cantor Fitzgerald Says Fortunes of F5 Networks Are About to Change

Canaccord Genuity Comments on Recent Journal Manuscripts Related to Thoratec Corporation's HeartMate II Device